BD Diagnostics and Lab21 are to collaborate to develop oncology assays for the BD MAX fully automated bench-top molecular system. Under the terms of the collaboration, Lab21 will develop polymerase chain reaction-based assays on the BD MAX platform for a series of oncology markers, while BD will be responsible for manufacturing and commercialising the tests worldwide.
UK NEQAS IMPROVES PATIENT CARE
We aim to improve patient care through monitoring the quality of tests and their reporting, in an independent manner and on a not-for-profit basis.
We are here to help ensure optimal quality in testing for the benefit of patients.
We believe that the result of tests should be:
The Haylofts, St Thomas Street, Haymarket, Newcastle, NE1 4LE, UK
7 April, 2026
ICC Belfast, Northern Ireland
13 - 16 April, 2026
Online
15 April, 2026
Edinburgh International Convention Centre
17-19 April, 2026
Messe München Munich, Germany
17-21 April, 2026
